Glob­al fund­ing for ne­glect­ed dis­ease R&D hit record high in 2017 — with meaty con­tri­bu­tions by UK, EC, In­dia and Ger­many

About a decade ago, in the throes of the glob­al fi­nan­cial cri­sis when most coun­tries fo­cused their re­sources on stim­u­lat­ing their do­mes­tic economies, the Unit­ed States’ NIH over­whelm­ing­ly con­tributed to glob­al fund­ing for ne­glect­ed dis­ease R&D. But oth­er na­tions are now catch­ing up. In 2017, glob­al in­vest­ment for ne­glect­ed dis­eases hit record lev­els at $3.5 bil­lion — the largest in­crease since 2008 — dri­ven large­ly by the UK and the Eu­ro­pean Com­mis­sion (EC), along with In­dia and Ger­many, ac­cord­ing to a key sur­vey fund­ed by the Bill and Melin­da Gates Foun­da­tion.

The G-FIND­ER sur­vey is con­duct­ed by Pol­i­cy Cures Re­search, which came out with its first re­port in 2008, track­ing glob­al pub­lic, pri­vate, and phil­an­thropic in­vest­ment in­to prod­uct R&D for ne­glect­ed dis­eases, which chiefly im­pact de­vel­op­ing coun­tries and are not giv­en sig­nif­i­cant R&D at­ten­tion. For the 2017 re­port, 197 or­ga­ni­za­tions com­plet­ed the sur­vey, which en­com­passed 33 ne­glect­ed dis­eases and all rel­e­vant prod­uct types: drugs, vac­cines, di­ag­nos­tics, mi­cro­bi­cides and vec­tor con­trol prod­ucts from ba­sic re­search to post-ap­proval stud­ies.

Mil­lions of lives are plagued by in­fec­tious dis­eases like HIV/AIDS, tu­ber­cu­lo­sis, and malar­ia or oth­er par­a­sitic dis­eases, which dis­pro­por­tion­ate­ly af­fect low and mid­dle in­come coun­tries — where ac­cess to health care, drink­ing wa­ter and hy­gien­ic liv­ing con­di­tions is not typ­i­cal­ly guar­an­teed. In­vest­ment to di­min­ish the bur­den of pover­ty-re­lat­ed and ne­glect­ed dis­eases, and their as­so­ci­at­ed mor­bid­i­ty and mor­tal­i­ty, is im­per­a­tive to ex­tri­cate suf­fer­ers from the vi­cious cy­cle of pover­ty and dis­ease. Ac­cord­ing to the END fund, ne­glect­ed trop­i­cal dis­eases af­fect more than 1.5 bil­lion of the world’s most im­pov­er­ished peo­ple, in­clud­ing 836 mil­lion chil­dren, and kill more than 170,000 peo­ple each year.

Da­ta from the G-FIND­ER re­port showed that glob­al in­vest­ment in­to ne­glect­ed dis­ease R&D jumped 7% ($232 mil­lion) over 2016, and in­di­cat­ed for the first time since 2009 that there has been two con­sec­u­tive years of growth in glob­al fund­ing for ne­glect­ed dis­ease R&D.

Back in 2009, the NIH pro­vid­ed near­ly 98% of the net over­all rise in spend­ing and most of those re­sources were di­rect­ed to­ward aca­d­e­m­ic in­sti­tu­tions that typ­i­cal­ly fo­cus on ba­sic re­search, as well as small US-based bio­phar­ma com­pa­nies. In 2017, the in­jec­tion dri­ven by in­vest­ments from the UK, EC, In­dia and Ger­many al­so came from the pub­lic sec­tor, but that fund­ing was chiefly di­rect­ed at or­ga­ni­za­tions that fo­cus on clin­i­cal tri­als and prod­uct de­vel­op­ment.

In­vest­ments from emerg­ing fun­ders, such as Uni­taid, Médecins Sans Fron­tières, Gavi, and the gov­ern­ments of Japan, In­dia and Brazil were un­der­scored for 2016, and each of these en­ti­ty’s raised their fund­ing in 2017 with the ex­cep­tion of Brazil, where a cap was im­posed on pub­lic sec­tor fund­ing. In­dia sharply raised its fund­ing by 38% ($21 mil­lion) — and ac­count­ed for the fourth largest pub­lic fun­der over­all. Mean­while South Africa al­so upped its con­tri­bu­tion by 24% ($2.7 mil­lion) — the largest ever in­vest­ment as a slice of GDP pro­vid­ed by a low- and mid­dle-in­come coun­try.

In terms of high in­come coun­tries, siz­able in­creas­es by the UK (up 89% or $87 mil­lion) and EC (up 50% or $40 mil­lion) nar­rowed the gap be­tween sec­ond and third high­est con­trib­u­tors and the biggest con­trib­u­tor of all — the US — which al­so lift­ed its fund­ing mar­gin­al­ly by 1.5% ($23 mil­lion).

De­spite hit­ting record highs in fund­ing in 2017, not a sin­gle gov­ern­ment met the WHO rec­om­men­da­tion that mem­ber states ded­i­cate at least 0.01% of their GDP to re­search in­to the health needs of de­vel­op­ing coun­tries, the re­port high­light­ed. “On­ly two coun­tries – the US with 0.0082% and the UK with 0.0071% – were even close, with no oth­er coun­try even reach­ing half the tar­get lev­el. In fact, over the 11 year his­to­ry of the G-FIND­ER re­port, on­ly the US has ever met this tar­get (which it did be­tween 2007 and 2012),” the re­port not­ed.

Fund­ing by the bio­phar­ma in­dus­try inched low­er in 2017 for both big phar­ma and small drug and de­vice de­vel­op­ers, fol­low­ing five con­sec­u­tive years of growth. But this may be due to de­vel­op­ments in in­dus­try pipelines — for ex­am­ple the no­table rise and fall in malar­ia drug fund­ing was dri­ven by the late-stage de­vel­op­ment and even­tu­al ap­proval of GSK’s malar­ia vac­cine tafeno­quine, now sold as Krintafel.

HIV/AIDS, malar­ia and tu­ber­cu­lo­sis to­geth­er in­spired more than two-thirds (70% or $2,496 mil­lion) of 2017 fund­ing, in line with pre­ced­ing years. With a pletho­ra of treat­ments akin to a cure now avail­able for hep C, the drop in fund­ing rel­e­gat­ed the dis­ease to the group of ail­ments that get less than 0.5% of glob­al fund­ing each year.


Im­age: SHUT­TER­STOCK

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

There’s nothing quite like a big patent win when it comes to burnishing your prospects in the pipeline. And for Amgen, which seems to have rescued Enbrel for a run to 2029, the cheering section on Wall Street is now fixed on AMG 510 and a key rival.

And it didn’t take much data to do it. 

There was the first snapshot of a handful of patients, with a 50% response rate. Then came word that Amgen researchers are also tracking responses in different cancers, at least one in colorectal cancer and appendiceal too. 

Bain's Or­ly Mis­han joins Pfiz­er's neu­ro spin­out Cerev­el; On­colyt­ic virus biotech taps Sil­la­Jen ex­ec He­le­na Chaye as CEO

→ Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations. 

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.